The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline/Tesaro; MSD; Sandoz
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline/Tesaro; MSD
Speakers' Bureau - AstraZeneca; GlaxoSmithKline/Tesaro; MSD
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline/Tesaro; MSD; Roche
Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study.
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; DECIPHERA; Genmab; GlaxoSmithKline; MERSANA; MSD Oncology; OxOnc; Pfizer; PharmaMar; Roche; Tesaro
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Mersana; Mersana; MSD Oncology; Pfizer; PharmaMar; Roche; Tesaro
Research Funding - BMS; MSD Oncology
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; French National Cancer Institute (INCA)
 
Aude Marie Savoye
No Relationships to Disclose
 
Marie-ange Mouret-Reynier
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Board participations and symposiums
 
Sylvie Chabaud
No Relationships to Disclose
 
Olfa Derbel
No Relationships to Disclose
 
Elsa Kalbacher
Honoraria - AstraZeneca; LEO Pharma; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; Roche; Tesaro/GSK
Travel, Accommodations, Expenses - AstraZeneca; LEO Pharma; Roche; Tesaro/GSK
 
Marianne Leheurteur
Leadership - AstraZeneca/Merck (Inst); daichi
Honoraria - Pfizer
Research Funding - daichi (Inst); MSD (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Mundipharma; Roche
 
Alejandra Martinez
No Relationships to Disclose
 
Corina Cornila
No Relationships to Disclose
 
Mathilde Martinez
No Relationships to Disclose
 
Leila Bengrine
No Relationships to Disclose
 
Frank Priou
No Relationships to Disclose
 
Nicolas Cloarec
Honoraria - Takeda
Consulting or Advisory Role - Takeda
Travel, Accommodations, Expenses - Pfizer
 
Laurence Venat-Bouvet
No Relationships to Disclose
 
Frederic Selle
No Relationships to Disclose
 
Dominique Berton
No Relationships to Disclose
 
Olivier Collard
No Relationships to Disclose
 
Florence Joly
Honoraria - Amgen; Astellas Pharma; AstraZeneca; GlaxoSmithKline; Ipsen; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Janssen; Roche
 
Olivier Tredan
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Lilly; MSD Oncology; Pfizer; Roche; Sandoz-Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Novartis; Pfizer; Roche